Raymond James Financial Services Advisors Inc. reduced its stake in Hill-Rom Holdings, Inc. (NYSE:HRC) by 11.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,620 shares of the medical technology company’s stock after selling 1,161 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Hill-Rom were worth $946,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. BDO Wealth Advisors LLC purchased a new position in Hill-Rom in the first quarter valued at approximately $29,000. Signaturefd LLC increased its stake in Hill-Rom by 53.3% in the first quarter. Signaturefd LLC now owns 302 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 105 shares during the last quarter. CWM Advisors LLC purchased a new position in Hill-Rom in the first quarter valued at approximately $39,000. Optimum Investment Advisors purchased a new position in Hill-Rom in the first quarter valued at approximately $50,000. Finally, CENTRAL TRUST Co increased its stake in Hill-Rom by 42.3% in the first quarter. CENTRAL TRUST Co now owns 690 shares of the medical technology company’s stock valued at $69,000 after purchasing an additional 205 shares during the last quarter. Institutional investors own 85.51% of the company’s stock.
In related news, SVP Mary Kay Ladone sold 3,125 shares of Hill-Rom stock in a transaction on Friday, June 26th. The shares were sold at an average price of $106.00, for a total value of $331,250.00. Following the transaction, the senior vice president now directly owns 13,566 shares in the company, valued at approximately $1,437,996. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Paul Sherwood Johnson sold 10,344 shares of Hill-Rom stock in a transaction on Friday, June 5th. The shares were sold at an average price of $103.95, for a total transaction of $1,075,258.80. Following the completion of the transaction, the senior vice president now owns 4,999 shares in the company, valued at $519,646.05. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,747 shares of company stock worth $1,657,089. 0.65% of the stock is currently owned by insiders.
Shares of HRC opened at $97.22 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.22 and a debt-to-equity ratio of 1.20. The firm has a market cap of $6.47 billion, a PE ratio of 44.60, a price-to-earnings-growth ratio of 1.36 and a beta of 0.72. The company’s 50 day simple moving average is $107.95 and its 200-day simple moving average is $105.06. Hill-Rom Holdings, Inc. has a 12-month low of $72.29 and a 12-month high of $117.68.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Friday, July 31st. The medical technology company reported $1.95 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.49. Hill-Rom had a net margin of 5.04% and a return on equity of 22.60%. The firm had revenue of $767.50 million for the quarter, compared to analyst estimates of $749.39 million. During the same period last year, the firm posted $1.23 EPS. Hill-Rom’s quarterly revenue was up 5.6% on a year-over-year basis. As a group, equities research analysts forecast that Hill-Rom Holdings, Inc. will post 5.44 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, September 18th will be given a $0.22 dividend. The ex-dividend date is Thursday, September 17th. This represents a $0.88 dividend on an annualized basis and a yield of 0.91%. Hill-Rom’s dividend payout ratio (DPR) is 17.32%.
Several equities analysts have commented on the stock. Needham & Company LLC dropped their price target on shares of Hill-Rom from $131.00 to $129.00 and set a “buy” rating on the stock in a research note on Friday. Barclays restated a “buy” rating and set a $125.00 target price on shares of Hill-Rom in a research report on Tuesday, April 14th. Finally, UBS Group lowered their target price on shares of Hill-Rom from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $125.80.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.